Accustem Sciences Inc. (ACUT)
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Accustem Sciences Inc.
OTC:ACUTHealthcare · Biotechnology
-9.23%$0.1180
Prev close$0.1300-9.23%Close$0.1180
Mkt Cap$1.9M
EV-
Float8.49M
O/S16.07M
VOL610 sh
$ Vol$74
RVOL0.22×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
MCap$1.9MFloat8.49MO/S16.07M
Dilution
No press releases found for ACUT.